Developability assessment of clinical drug products with maximum absorbable doses

International Journal of Pharmaceutics

Volumn 427, Issue 2, 2012, Pages 260-269

  Ding, Xuan ^a   Rose, John P ^a   Van Gelder, Jan ^b  

^a ELI LILLY AND COMPANY   (United States)

^b JOHNSON AND JOHNSON   (United States)

Author keywords

Developability assessment; Drug absorption; GastroPlus ; Maximum absorbable dose; Simulation

Indexed keywords

ATENOLOL; CARBAMAZEPINE; CIMETIDINE; DESIPRAMINE; ENALAPRILAT; FLUINDOSTATIN; FOSINOPRIL; FUROSEMIDE; HYDROCHLOROTHIAZIDE; KETOPROFEN; METOPROLOL; NAPROXEN; PHENAZONE; PROPRANOLOL; RANITIDINE; TERBUTALINE; VERAPAMIL;

ARTICLE; COMPUTER PROGRAM; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG FORMULATION; DRUG PENETRATION; GASTROINTESTINAL ABSORPTION; JEJUNUM; MAXIMUM ABSORBABLE DOSE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; VALIDATION STUDY;

ADMINISTRATION, ORAL; ALGORITHMS; AREA UNDER CURVE; ARTIFICIAL INTELLIGENCE; CHEMISTRY, PHARMACEUTICAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COMPUTER SIMULATION; DRUG DESIGN; INTESTINAL ABSORPTION; PARTICLE SIZE; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; SOLUBILITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

EID: 84859104300     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2012.02.003     Document Type: Article

References (39)

1. M.H. Abraham, Y.H. Zhao, J. Le, A. Hersey, C.N. Luscombe, D.P. Reynolds, G. Beck, B. Sherborne, and I. Cooper On the mechanism of human intestinal absorption Eur. J. Med. Chem. 37 2002 595 605
2. A. Aburub, D.S. Risley, and D. Mishra A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe Int. J. Pharm. 347 2008 16 22
3. P. Artursson, and J. Karlsson Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 175 1991 880 885
4. K.L. Audus, R.L. Bartel, I.J. Hidalgo, and R.T. Borchardt The use of cultured epithelial and endothelia cells for drug transport and metabolism studies Pharm. Res. 7 1990 435 451
5. A. Ayrton, and P. Morgan Role of transport proteins in drug absorption, distribution and excretion Xenobiotica 31 2001 469 497
6. V. Bakatselou, R.C. Oppenheim, and J.B. Dressman Solubilization and wetting effects of bile salts on the dissolution of steroids Pharm. Res. 8 1991 1461 1499
7. D.E. Clark, and P.D.J. Grootenhuis Predicting passive transport in silico: history, hype, hope Curr. Top. Med. Chem. 3 2003 1193 1203
8. J.B. Dressman, G.L. Amidon, C. Reppas, and V.P. Shah Dissolution testing as a prognostic tool for oral drug absorption: immediate-release dosage forms Pharm. Res. 15 1998 11 22
9. J.B. Dressman, M. Vertzoni, K. Goumas, and C. Reppas Estimating drug solubility in the gastrointestinal tract Adv. Drug Deliv. Rev. 59 2007 591 602
10. W.J. Egan, and G. Lauri Prediction of intestinal permeability Adv. Drug Deliv. Rev. 54 2002 273 289
11. P.O. Gubbins, and K.E. Bertch Drug absorption in gastrointestinal disease and surgery. Clinical pharmacokinetic and therapeutic implications Clin. Pharmacokinet. 21 1991 431 447
12. M. Hariharan, L.D. Ganokar, G.E. Amidon, A. Cavallo, P. Gatti, M.J. Hageman, I. Choo, J.L. Miller, and U.J. Shah Reducing the time to develop and manufacture formulations for first oral dose in humans Pharm. Technol. October 2003 68 84
13. X. He Integration of physical, chemical, mechanical, and biopharmaceutical properties in solid oral dosage form development Y. Qiu, Y. Chen, G.Z. Zhang, Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice 2009 Elsevier Inc. Oxford, UK 407 441
14. R.J. Hintz, and K.C. Johnson The effect of particle size distribution on the dissolution rate and oral absorption Int. J. Pharm. 51 1989 9 17
15. L.F. Huang, and W.Q. Tong Impact of solid state properties in developability assessment of drug candidate Adv. Drug Deliv. Rev. 56 2004 321 334
16. K.C. Johnson, and A.C. Swindell Guidance in the setting of drug particle size specifications to minimize variability in absorption Pharm. Res. 13 1996 1795 1798
17. K.C. Johnson Dissolution and absorption modeling: model expansion to simulate the effects of precipitation, water absorption, longitudinally changing intestinal permeability, and controlled release on drug absorption Drug Dev. Ind. Pharm. 29 2003 833 842
18. E.S. Kostewicz, M. Wunderlich, U. Brauns, R. Becker, T. Bock, and J.B. Dressman Predicting the precipitation of poorly soluble weak bases upon entry in the small intestine J. Pharm. Pharmacol. 56 2004 43 51
19. W. Kromer Endogenous and exogenous opioids in the control of gastrointestinal motility and secretion Pharmacol. Rev. 40 1988 121 162
20. H. Lennernäs, Ö. Ahrenstedt, R. Hällgren, L. Knutson, M. Ryde, and L. Paalzow Regional jejunal perfusion, a new in vivo approach to study oral drug absorption in man Pharm. Res. 9 1992 1243 1251
21. H. Lennernäs, K. Palm, U. Fagerholm, and P. Artursson Comparison between active and passive drug transport in human intestinal epithelial (Caco-2) cells in vitro and human jejunum in vivo Int. J. Pharm. 127 1996 103 107
22. H. Lennernäs Human intestinal permeability J. Pharm. Sci. 87 1998 403 410
23. E. Merisko-Liversidge, G.G. Liversidge, and E.R. Cooper Nanosizing: a formulation approach for poorly water-soluble compounds Eur. J. Pharm. Sci. 18 2004 113 120
24. S. Neuhoff, A.-L. Ungell, I. Zamora, and P. Artusson pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions Pharm. Res. 20 2003 1141 1148
25. S. Neuhoff, A.-L. Ungell, I. Zamora, and P. Artusson pH-dependent passive and active transport of acidic drugs across Caco-2 cell monolayers Eur. J. Pharm. Sci. 25 2005 211 220
26. D-M. Oh, R.L. Curl, and G.L. Amidon Estimating the fraction dose absorbed from suspensions of poorly soluble compounds in humans Pharm. Res. 10 1993 264 270
27. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug Discov. 2007 6231 6248
28. V. Saxena, R. Panicucci, Y. Joshi, and S. Garad Developability assessment in pharmaceutical industry: an integrated group approach for selecting developable candidates J. Pharm. Sci. 98 2009 1962 1979
29. A.T. Serajuddin Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs J. Pharm. Sci. 88 1999 1058 1066
30. D.T. Stanton, B.E. Mattioni, J.J. Knittel, and P.C. Jurs Development and use of hydrophobic surface area (HAS) descriptors for computer-assisted quantitative structure-activity and structure-property relationship studies J. Chem. Inf. Comput. Sci. 44 2004 1010 1023
31. D. Sun, L.X. Yu, M.A. Hussain, D.A. Wall, R.L. Smith, and G.L. Amidon In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome Curr. Opin. Drug Discov. Devel. 7 2004 75 85
32. S.C. Sutton Role of physiological intestinal water in oral absorption AAPS J. 11 2009 277 285
33. R. Takano, N. Takata, R. Saito, K. Furumoto, S. Higo, Y. Hayashi, M. Machida, Y. Aso, and S. Yamashita Quantitative analysis of the effect of supersaturation on in vivo drug absorption Mol. Pharmaceutics 7 2010 1431 1440
34. D.A. Volpe Variability in Caco-2 and MDCK cell-based intestinal permeability assay J. Pharm. Sci. 97 2008 712 725
35. T.S. Wiedmann, and L. Kamel Examination of the solubilization of drugs by bile salt micelles J. Pharm. Sci. 91 2002 1743 1764
36. S. Winiwarter, N.M. Bonham, F. Ax, A. Hallberg, H. Lennernäs, and A. Karlén Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach J. Med. Chem. 41 1998 4939 4949
37. L.X. Yu, J.R. Crison, and G.L. Amidon A strategic approach for predicting oral drug absorption Pharm. Res. 12 1995 S8
38. L. Yu, and G.L. Amidon Characterization of small intestinal transit time distribution in humans Int. J. Pharm. 171 1998 157 163
39. L.X. Yu An integrated model for determining causes of poor oral drug absorption Pharm. Res. 16 1999 1883 1887